Loxo Oncology to Announce Fourth Quarter and Year-End 2016 Financial Results

STAMFORD, Conn., Feb. 28, 2017 -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, will announce financial results for the fourth quarter and full year ended December 31, 2016 on March 7, 2017 before the NASDAQ market open.

The company will not be conducting a conference call in conjunction with this earnings release.

About Loxo Oncology

Loxo Oncology is a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers. Our pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. We believe that the most selective, purpose-built medicines have the highest probability of maximally inhibiting the intended target, thereby delivering best-in-class disease control and safety. Our management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver new cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company's website at www.loxooncology.com.

Contacts for Loxo Oncology, Inc.

Company:
Jacob S. Van Naarden
Chief Business Officer
[email protected]

Investors:
Peter Rahmer
The Trout Group, LLC
646-378-2973
[email protected]

Media:
Dan Budwick
Pure Communications, Inc.
973-271-6085
[email protected]